Categorynews

Insights on the Buccal Drug Delivery Systems Global Market to 2028 – Featuring Pfizer, Catalent and Endo Pharmaceuticals Among Others – ResearchAndMarkets.com

April 12, 2022 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Buccal Drug Delivery Systems Market Size, Share & Trends Analysis Report By Type (Buccal Tablets & Lozenges, Sublingual Films), By Application, By End-user, By Region, And Segment Forecasts, 2021 – 2028” report has been added to ResearchAndMarkets.com’s offering.

The global buccal drug delivery systems market size is expected to reach USD 5.9 billion by 2028, according to a new report by the publisher. The market is expected to expand at a CAGR of 9.2% from 2021 to 2028.

Companies Mentioned

  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Glaxo Smith Klein
  • Indivior Pharmaceuticals
  • Catalent
  • Generex Biotechnology
  • Biodelivery Sciences International, Inc.
  • Endo Pharmaceuticals
  • ARx LLC
  • Cynapsus Therapeutic Inc.

Buccal drug delivery systems have gained significant momentum since the last decade. Elimination of first-pass metabolism, quick absorption of the pH-sensitive drug, no interaction with stomach acid, quicker onset of action than any oral dose, minimal side effects, and reduced drug degradation are some of the factors fueling the market growth. Buccal drug delivery has gained large acceptance among geriatric patients and patients having difficulty swallowing.

Leading players like Generex, NovaDel, Biodiversity Sciences International, and Transcept Pharmaceuticals are constantly developing critical drugs like insulin, heparin, morphine, long-lasting pain analgesics, and some anti cardiac drugs into rapid mists, mucoadhesive discs, and lozenges.

Commercialization of this research would eventually lead to being a major life savior as it would ensure the faster onset of action and eliminate drug degradation. Despite the increased R&D activity among market players, a steep decline was observed in the sales and revenue gains due to the outbreak of the Covid-19 pandemic. Except for COVID medications, several other drug markets were majorly hit leading to the dip in the market for buccal drug delivery. However, it is expected to bounce back by 2022.

Buccal Drug Delivery Systems Market Report Highlights

  • The buccal tablets and lozenges type segment accounted for the largest revenue share in 2020 due to its wider acceptance among patients
  • The smoking cessation application segment held the largest share in 2020. Buccal drug delivery is often the most preferred and effective formulation for treating patients with smoking or nicotine addiction
  • The hospital end-user segment captured the largest revenue share in 2020 owing to a large number of admissions of geriatric patients and abundant medication supplies
  • North America held the largest revenue share in 2020 due to a large number of leading manufacturers and growing research in the region

Key Topics Covered:

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Buccal drug delivery system Market Variables, Trends & Scope

3.1. Market Lineage Outlook

3.1.1. Parent market outlook

3.1.2. Related/ancillary market outlook

3.2. Penetration & Growth Prospect Mapping

3.3. Industry Value Chain Analysis

3.3.1. Reimbursement framework

3.4. Market Dynamics

3.4.1. Market driver analysis

3.4.1.1. Improved research in this field

3.4.1.2. Large number of market players

3.4.2. Market restraint analysis

3.4.2.1. Critical formulation process

3.5. Buccal drug delivery system Market Analysis Tools

Chapter 4. Buccal drug delivery system: Type Estimates & Trend Analysis

4.1. Definitions and Scope

4.1.1. Sublingual Films

4.1.2. Buccal Tablets and lozenges

4.1.3. Oral sprays

4.2. Buccal drug delivery system Market Share, 2021 & 2028

4.3. Segment Dashboard

4.4. Global Buccal drug delivery system Market by Type Outlook

4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following

4.5.1. Sublingual films

4.5.1.1. Sublingual film-based Market estimates and forecast 2016 to 2028 (USD Million)

4.5.2. Buccal Tablets and lozenges

4.5.2.1. Buccal Tablets and lozenges-based Market estimates and forecast 2016 to 2028 (USD Million)

4.5.3. Oral Sprays

4.5.3.1. Oral sprays-based Market estimates and forecast 2016 to 2028 (USD Million)

Chapter 5. Buccal drug delivery system: Application Estimates & Trend Analysis

5.1. Definitions and Scope

5.1.1. Pain Management

5.1.2. Smoking Cessation

5.1.3. Angina Pectoris

5.1.4. Others

5.2. Buccal drug delivery system Market Share, 2021 & 2028

5.3. Segment Dashboard

5.4. Global Buccal drug delivery system Market by application Outlook

5.5. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following

5.5.1. Pain management

5.5.1.1. Pain management Market estimates and forecast 2016 to 2028 (USD Million)

5.5.2. Smoking Cessation

5.5.2.1. Smoking Cessation Market estimates and forecast 2016 to 2028 (USD Million)

5.5.3. Angina Pectoris

5.5.3.1. Angina Pectoris Market estimates and forecast 2016 to 2028 (USD Million)

5.5.4. Others

5.5.4.1. Others Market estimates and forecast 2016 to 2028 (USD Million)

Chapter 6. Buccal drug delivery system: End-user Estimates & Trend Analysis

Chapter 7. Buccal drug delivery system Market: Regional Estimates & Trend Analysis

Chapter 8. Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/r/6xxema

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900